Indena at DCAT 2022 presents its latest innovation in CDMO services

Milan, 21 March 2022 – The further expansion of its existing GMP Pilot Plant for active pharmaceutical ingredients, the doubling of its kilo lab LK2 for OEB 5 products and the installation of a 250-liter industrial hydrogenator: these are the latest innovations Indena is presenting at DCAT 2022 and which confirm that CDMO activities are the priority in the company’s strategic vision.

“Aiming to provide customers with an increasing breadth of services, we have been investing in the implementation of cutting-edge technologies while capitalizing on decades of know-how in the field of complex molecules – explains Stefano Togni, Chief Commercial Officer of Indena S.p.A. –The combination of Indena’s expertise with state-of-the-art facilities allows us to deliver products and processes that range from small-scale orders for GMP batches for clinical use to large commercial manufacturing supplies”.

Indena has completed in 2020 the installation of a GMP pilot plant, to complement its large industrial capacity. In the last months, Indena has been working on further expanding its GMP pilot plant with a second suite equipped with 10,000 L reactors, thus expanding the system and exploiting Indena’s technologies also on these intermediate scales. Indena's goal is to offer customers the ability to run synthetic processes in a wide range of scale and conditions for both natural molecules, semisynthetic and fully synthetic ones.

Furthermore, Indena has more than doubled the capacity of its kilo lab LK2 for OEB 5 products. As a matter of fact, the new kilo lab will be capable of running larger-scale (60 L) reactions. This expansion completes Indena's production capacity for HPAPIs, allowing the company to offer different capacities for products at the highest containment level (OEL 20 ng/m3 or OEB5).

Another important step of Indena’s CDMO development is the installation of a 250 L hydrogenator, which will be ready by 2022. Together with the existing 20 L hydrogenator, the new one will allow the company to meet market requests, also for this kind of chemical reaction, in the most efficient and flexible way.

“Indena is a full service provider and a reliable partner for the cGMP contract development and production of active and highly potent pharmaceutical ingredients – says Pietro Allegrini, R&D Director of Indena S.p.A. – Our reliability is rooted in one hundred year history and in our longstanding leadership in the field of botanical active ingredients. On the other hand, since years we’ve been focusing to the HPAPI production, introducing equipment and soft skills devoted to such specific field in our plants. That allows us to effectively support leading pharmaceutical and biotech companies in creating successful product, for the benefit of end users”.

Meet Indena at DCAT 2022
21-24 March 2022 – New York City
Further information at Indena CDMO.
To keep updated about CDMO innovations at #DCATWeek 2022 visit our NY DCAT DIARY page and follow #IndenaNYDiaries on our social media.